Research Progress on The Mechanism and Treatment of Inflammatory Response in Myocardial Ischemia-Reperfusion Injury
DOI:
https://doi.org/10.1532/hsf.4725Keywords:
Acute myocardial infarction, myocardial ischemia-reperfusion injury, NLR, caspase, interleukinAbstract
Acute myocardial infarction can be treated aggressively with intravenous thrombolysis, percutaneous coronary intervention, and coronary artery bypass grafting; however, recanalization can cause myocardial ischemia-reperfusion injury (MIRI). This is an important reason that restricts the treatment effect of patients. After the ischemic myocardium is restored to perfusion, an inflammatory response can occur within minutes and peak within a few days. Many pro-inflammatory cytokines can seriously damage cardiac function. Inflammation can regulate cardiomyocyte apoptosis, autophagy, pyroptosis, and necrosis, and is the main initiating factor leading to MIRI in cardiomyocytes.
This article reviews the mechanism of inflammatory response in the ischemia-reperfusion period after acute myocardial infarction and the clinical value and application prospect of inhibiting inflammatory response in the treatment of acute myocardial infarction.
References
Audia JP, Yang XM, Crockett ES, et al. 2018. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function[J]. Basic Res Cardiol. 113(5):32.
Babamale AO, Chen ST. 2021. Nod-like Receptors: Critical Intracellular Sensors for Host Protection and Cell Death in Microbial and Parasitic Infections[J]. Int J Mol Sci. 22(21).
Chen L, Liu P, Feng X, et al. 2017. Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo[J]. J Cell Mol Med. 21(12):3178-3189.
Dabouz R, Cheng CWH, Abram P, et al. 2020. An allosteric interleukin-1 receptor modulator mitigates inflammation and photoreceptor toxicity in a model of retinal degeneration[J]. Journal of Neuroinflammation. 17(1).
Davidson SM, Ferdinandy P, Andreadou I, et al. 2019. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury[J]. Journal of the American College of Cardiology. 73(1):89-99.
de Dios C, Bartolessis I, Roca-Agujetas V, et al. 2019. Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress[J]. Redox Biol. 26:101283.
DeFilippis AP, Chapman AR, Mills NL, et al. 2019. Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury[J]. Circulation. 140(20):1661-1678.
Do CH, Arjun S, Petrucci O, et al. 2018. The Caspase 1 Inhibitor VX-765 Protects the Isolated Rat Heart via the RISK Pathway[J]. Cardiovasc Drugs Ther. 32(2):165-168.
Fan Q, Tao R, Zhang H, et al. 2019. Dectin-1 Contributes to Myocardial Ischemia/Reperfusion Injury by Regulating Macrophage Polarization and Neutrophil Infiltration[J]. Circulation. 139(5):663-678.
Fearon WF, Fearon DT. 2008. Inflammation and Cardiovascular Disease[J]. Circulation. 117(20):2577-2579.
Frati G, Schirone L, Chimenti I, et al. 2017. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy[J]. Cardiovasc Res. 113(4):378-388.
Huang XW, Pan MD, Du PH, et al. 2018. Arginase-2 protects myocardial ischemia-reperfusion injury via NF-kappaB/TNF-alpha pathway[J]. Eur Rev Med Pharmacol Sci. 22(19):6529-6537.
Jacotot É. 2020. Inhibition des caspases[J]. médecine/sciences. 36(12):1143-1154.
Jia X, Yan R, Lin H, et al. 2022. TBBPA and its alternative TCBPA induced ROS-dependent mitochondria-mediated apoptosis in the liver of Rana nigromaculata[J]. Environ Pollut. 297:118791.
Kleveland O, Kunszt G, Bratlie M, et al. 2016. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial[J]. Eur Heart J. 37(30):2406-2413.
Lafuse WP, Wozniak DJ, Rajaram M. 2020. Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair[J]. Cells. 10(1).
Li D, Yang S, Xing Y, et al. 2021. Novel Insights and Current Evidence for Mechanisms of Atherosclerosis: Mitochondrial Dynamics as a Potential Therapeutic Target[J]. Front Cell Dev Biol. 9:673839.
Li X, Yao X, Zhu Y, et al. 2019. The Caspase Inhibitor Z-VAD-FMK Alleviates Endotoxic Shock via Inducing Macrophages Necroptosis and Promoting MDSCs-Mediated Inhibition of Macrophages Activation[J]. Frontiers in Immunology. 10.
Liang H, Sun Y, Gao A, et al. 2019. Ac-YVAD-cmk improves neurological function by inhibiting caspase-1-mediated inflammatory response in the intracerebral hemorrhage of rats[J]. Int Immunopharmacol. 75:105771.
Lu QY, Ma JQ, Duan YY, et al. 2019. Carthamin Yellow Protects the Heart Against Ischemia/Reperfusion Injury With Reduced Reactive Oxygen Species Release and Inflammatory Response[J]. J Cardiovasc Pharmacol. 74(3):228-234.
Ma Z, Li K, Chen P, et al. 2020. Propofol Attenuates Inflammatory Damage via Inhibiting NLRP1-Casp1-Casp6 Signaling in Ischemic Brain Injury[J]. Biological & pharmaceutical bulletin. 43(10):1481-1489.
Mastrocola R, Penna C, Tullio F, et al. 2016. Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways[J]. Oxidative Medicine and Cellular Longevity. 2016:1-11.
McKernan DP. 2020. Pattern recognition receptors as potential drug targets in inflammatory disorders[J]. Advances in protein chemistry and structural biology. 119:65-109.
Mocanu MM, Baxter GF, Yellon DM. 2000. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury[J]. Br J Pharmacol. 130(2):197-200.
Monnier PP, D'Onofrio PM, Magharious M, et al. 2011. Involvement of caspase-6 and caspase-8 in neuronal apoptosis and the regenerative failure of injured retinal ganglion cells[M].
Munjal A, Khandia R. 2020. Atherosclerosis: orchestrating cells and biomolecules involved in its activation and inhibition[J]. Adv Protein Chem Struct Biol. 120:85-122.
Nagyőszi P, Nyúl-Tóth Á, Fazakas C, et al. 2015. Regulation of NOD-like receptors and inflammasome activation in cerebral endothelial cells[J]. Journal of Neurochemistry. 135(3):551-564.
Perrin C, Ecarnot-Laubriet A, Vergely C, et al. 2003. Calpain and caspase-3 inhibitors reduce infarct size and post-ischemic apoptosis in rat heart without modifying contractile recovery[J]. Cell Mol Biol (Noisy-le-grand). 49 Online Pub:L497-L505.
Pluijmert NJ, Bart CI, Bax WH, et al. 2020. Effects on cardiac function, remodeling and inflammation following myocardial ischemia-reperfusion injury or unreperfused myocardial infarction in hypercholesterolemic APOE*3-Leiden mice[J]. Sci Rep. 10(1):16601.
Qin Q, Liu H, Shou J, et al. 2021. The inhibitor effect of RKIP on inflammasome activation and inflammasome-dependent diseases[J]. Cell Mol Immunol. 18(4):992-1004.
Rudolphi K, Gerwin N, Verzijl N, et al. 2003. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis[J]. Osteoarthritis Cartilage. 11(10):738-746.
Shah PK, Lecis D. 2019. Inflammation in atherosclerotic cardiovascular disease [version 1; peer review: 4 approved][J]. F1000 research. 8:1402.
Tan Y, Mui D, Toan S, et al. 2020. SERCA Overexpression Improves Mitochondrial Quality Control and Attenuates Cardiac Microvascular Ischemia-Reperfusion Injury[J]. Mol Ther Nucleic Acids. 22:696-707.
Tenthorey JL, Haloupek N, Lopez-Blanco JR, et al. 2017. The structural basis of flagellin detection by NAIP5: A strategy to limit pathogen immune evasion[J]. Science. 358(6365):888-893.
van Hout GPJ, Bosch L, Ellenbroek GHJM, et al. 2016. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction[J]. European Heart Journal. w247.
Wang D, Lv L, Xu Y, et al. 2021. Cardioprotection of Panax Notoginseng saponins against acute myocardial infarction and heart failure through inducing autophagy[J]. Biomed Pharmacother. 136:111287.
Wang J, Zhou H. 2020. Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia–reperfusion injury[J]. Acta Pharmaceutica Sinica B. 10(10):1866-1879.
Zhang J, Huang L, Shi X, et al. 2020. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway[J]. Aging (Albany NY). 12(23):24270-24287.
Zhou H, Ren J, Toan S, et al. 2021. Role of mitochondrial quality surveillance in myocardial infarction: From bench to bedside[J]. Ageing Res Rev. 66:101250.
Zhu H, Tan Y, Du W, et al. 2021. Phosphoglycerate mutase 5 exacerbates cardiac ischemia-reperfusion injury through disrupting mitochondrial quality control[J]. Redox Biol. 38:101777.
Zhu H, Toan S, Mui D, et al. 2021. Mitochondrial quality surveillance as a therapeutic target in myocardial infarction[J]. Acta Physiol (Oxf). 231(3):e13590.
Zhu J, Huang J, Dai D, et al. 2019. Recombinant human interleukin-1 receptor antagonist treatment protects rats from myocardial ischemia–reperfusion injury[J]. Biomedicine & Pharmacotherapy. 111:1-5.
